Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 22 January 2026

Sec. Cancer Immunity and Immunotherapy

Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1788767

Correction: Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis

Minyan YeMinyan Ye1Yinuo DongYinuo Dong2Xiaoyun Li,Xiaoyun Li2,3Yang ZhiYang Zhi2Yuping LuYuping Lu1Jieting TangJieting Tang2Wei ZhongWei Zhong2Xiaohong LeiXiaohong Lei2Yimin Mao*Yimin Mao2*Sha Huang*Sha Huang1*Yanyan Song*Yanyan Song4*
  • 1Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China
  • 2Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Diseases, National Health Commission (NHC) Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  • 3Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fujian Clinical Research Center for Liver and Intestinal Diseases, Fuzhou, Fujian, China
  • 4Department of Biostatistics, Clinical Research Institute, Shanghai Jiaotong University School of Medicine, Shanghai, China

A Correction on
Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis

By Ye M, Dong Y, Li X, Zhi Y, Lu Y, Tang J, Zhong W, Lei X, Mao Y, Huang S and Song Y (2026) Front. Immunol. 16:1677998. doi: 10.3389/fimmu.2025.1677998

The order of authors in the author list of the published paper was erroneously given as:

“Minyan Ye1, Yinuo Dong2, Xiaoyun Li2,3, Yang Zhi2, Yuping Lu1, Jieting Tang2, Wei Zhong2, Xiaohong Lei2, Yanyan Song4*, Sha Huang1* and Yimin Mao2*

The correct author list reads:

“Minyan Ye1, Yinuo Dong2, Xiaoyun Li2,3, Yang Zhi2, Yuping Lu1, Jieting Tang2, Wei Zhong2, Xiaohong Lei2, Yimin Mao2*, Sha Huang1* and Yanyan Song4*

The original version of this article has been updated.

The funder “the National Key R&D Program of China, (2022YFC3502101) to “Yimin Mao” was erroneously omitted.

The funder “National Natural Science Foundation of China, (NSFC 82270619, NSFC 82470621) to “Yimin Mao” was erroneously omitted.

The funder “Joint Funds for the Innovation of Science and Technology, Fujian Province, (2021Y9218) to “Sha Huang” was erroneously omitted.

The funder “Natural Science Foundation of Fujian Province, (2023J011296) to “Sha Huang” was erroneously omitted.

The funder “the Scientific Research Foundation of Fujian Cancer Hospital, (F2326Y-YZK04-02) to “Sha Huang” was erroneously omitted.

The original version of this article has been updated.

In the published article, there was a mistake in the Funding statement. The funding statement was describe as “The author(s) declared that financial support was not received for this work and/or its publication”.

A correction has been made to the section Funding, Page 11:

“This work was supported by the National Key R&D Program of China (2022YFC3502101), National Natural Science Foundation of China (NSFC 82270619, NSFC 82470621), Joint Funds for the Innovation of Science and Technology, Fujian Province (2021Y9218), Natural Science Foundation of Fujian Province (2023J011296), and the Scientific Research Foundation of Fujian Cancer Hospital (F2326Y-YZK04-02).”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: advanced effect, immunotherapy, LAG-3, meta - analysis, safety, TIGIT

Citation: Ye M, Dong Y, Li X, Zhi Y, Lu Y, Tang J, Zhong W, Lei X, Mao Y, Huang S and Song Y (2026) Correction: Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis. Front. Immunol. 17:1788767. doi: 10.3389/fimmu.2026.1788767

Received: 15 January 2026; Accepted: 16 January 2026;
Published: 22 January 2026.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2026 Ye, Dong, Li, Zhi, Lu, Tang, Zhong, Lei, Mao, Huang and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yimin Mao , bWFveW0xMTk2OEAxNjMuY29t; Sha Huang , aHVhbmdzaGEwMjEwQDE2My5jb20=; Yanyan Song , eWFueWFuc29uZ0BzanR1LmVkdS5jbg==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.